welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)

key information

study id #: NCT03907072

condition: Duchenne Muscular Dystrophy

status: terminated


This is a Phase 2/3, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension period to evaluate the safety and efficacy of WVE-210201 (suvodirsen) in ambulatory male pediatric patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping intervention (DYSTANCE 51)

intervention: WVE-210201 (Suvodirsen), Placebo

mechanism of action: Exon-skipping to promote dystrophin production

results: https://clinicaltrials.gov/ct2/show/results/NCT03907072

last updated: January 31, 2020